Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 126

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 126
---
388 57 %$11,625 87 %Stock compensation5,431 18 %9,809 41 %(4,378)(45)%Depreciation and amortization505 2 %513 2 %(8)(2)%Total general & administrative expenses$30,949 100 %$23,710 100 %$7,239 31 %

(in thousands)Nine Months Ended June 30, 2025% ofExpenseCategory Nine Months Ended June 30, 2024% ofExpenseCategory Increase (Decrease)$% Salaries$23,152 27 %$20,087 28 %$3,065 15 %Professional, outside services, and other35,811 41 %16,910 23 %18,901 112 %Facilities related4,546 5 %3,278 5 %1,268 39 %Total general & administrative expense, excluding non-cash expense$63,509 73 %$40,275 56 %$23,234 58 %Stock compensation21,230 25 %30,759 42 %(9,529)(31)%Depreciation and amortization1,525 2 %1,350 2 %175 13 %Total general & administrative expense$86,264 100 %$72,384 100 %$13,880 19 %

Salaries expense increased $1.2 million, or 18%, for the three months ended June 30, 2025 and $3.1 million, or 15%, for the nine months ended June 30, 2025 compared to the same periods of 2024. The increase was driven by the combination of annual salary increases and an increase in headcount required to support the Company’s growth as the Company prepares for commercialization. 

Professional, outside services, and other expenses include costs related to legal, audit, consulting, patent filings, business insurance, other external services, as well as travel, communication, and technology expenses. These expenses 

32

increased $9.5 million, or 175%, for the three months ended June 30, 2025 and $18.9 million, or 112%, for the nine months ended June 30, 2025 compared to the same periods of 2024. The increase for both periods were mainly due to